goodrx helps americans save on prescriptions. americans spend over $400 billion a year on prescriptions, and too many people simply can't find affordable prescriptions. even if you have insurance or medicare. we offer a website and mobile apps that gathers current prices, powerful savings tips and valuable discounts for every prescription drug at virtually every pharmacy in the us. goodrx is used by thousands of physicians and millions of americans each month. we have saved americans over $3 billion. we're not going to rest until prescriptions are affordable for all americans. we also offer goodrx for benefits, which provides technology solutions for health plans, payors and pbm's in an easy-to-understand website and mobile app experience. learn more at www.goodrx.com/benefits.
Company profile
Ticker
GDRX
Exchange
Website
CEO
Doug Hirsch
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
GoodRx Intermediate Holdings, LLC • GoodRx, Inc. • Iodine, Inc. • GoodRx Care, LLC • Lighthouse Acquisition Corp. • Scriptcycle, LLC • HealthiNation Inc. • RxSaver, Inc. • Buckeye Acquisition, LLC • flipMD, Inc. ...
IRS number
475104396
GDRX stock data
Latest filings (excl ownership)
8-K
Company Announces Board Resignations
14 Mar 24
8-K
Departure of Directors or Certain Officers
7 Mar 24
8-K
Other Events
7 Mar 24
S-8
Registration of securities for employees
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Goodrx Reports Fourth Quarter and Full Year 2023 Results
29 Feb 24
8-K
Entry into a Material Definitive Agreement
23 Feb 24
8-K
Departure of Directors or Certain Officers
17 Jan 24
8-K
GoodRx Announces Preliminary Fourth Quarter and Full Year 2023 Results and Early Expectations for First Quarter and Full Year 2024
10 Jan 24
8-K
GoodRx Appoints Kelly J. Kennedy to Board of Directors
22 Dec 23
Transcripts
GDRX
Earnings call transcript
2023 Q4
29 Feb 24
GDRX
Earnings call transcript
2023 Q3
9 Nov 23
GDRX
Earnings call transcript
2023 Q2
9 Aug 23
GDRX
Earnings call transcript
2023 Q1
10 May 23
GDRX
Earnings call transcript
2022 Q4
28 Feb 23
GDRX
Earnings call transcript
2022 Q3
9 Nov 22
GDRX
Earnings call transcript
2022 Q2
8 Aug 22
GDRX
Earnings call transcript
2022 Q1
9 May 22
GDRX
Earnings call transcript
2021 Q4
1 Mar 22
GDRX
Earnings call transcript
2021 Q3
11 Nov 21
Latest ownership filings
4
Scott Wagner
19 Mar 24
4
Romin Nabiey
14 Mar 24
4
Karsten Voermann
14 Mar 24
4
Romin Nabiey
8 Mar 24
4
Karsten Voermann
8 Mar 24
4
Change in insider ownership
8 Mar 24
4
Change in insider ownership
8 Mar 24
SC 13D/A
FRANCISCO PARTNERS IV, L.P.
8 Mar 24
SC 13D/A
Spectrum Equity VII, L.P.
8 Mar 24
4
Douglas Joseph Hirsch
1 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 794.91 mm | 794.91 mm | 794.91 mm | 794.91 mm | 794.91 mm | 794.91 mm |
Cash burn (monthly) | (no burn) | (no burn) | 15.53 mm | 1.81 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 92.34 mm | 10.77 mm | n/a | n/a |
Cash remaining | n/a | n/a | 702.56 mm | 784.14 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 45.2 | 432.9 | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 161 |
Opened positions | 33 |
Closed positions | 24 |
Increased positions | 43 |
Reduced positions | 45 |
13F shares | Current |
---|---|
Total value | 778.91 bn |
Total shares | 332.13 mm |
Total puts | 517.90 k |
Total calls | 535.60 k |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
Francisco Partners Management | 84.70 mm | $476.86 bn |
Francisco Partners Iv | 84.70 mm | $2.53 bn |
Idea Men | 50.16 mm | $0.00 |
Spectrum Equity VII | 48.15 mm | $1.44 bn |
Vanguard | 8.68 mm | $48.87 bn |
Silver Lake Group, L.L.C. | 3.53 mm | $19.89 bn |
The Hirsch Family Irrevocable Trust | 3.12 mm | $101.96 mm |
Bezdek Family Irrevocable Trust | 3.12 mm | $101.96 mm |
Renaissance Technologies | 2.74 mm | $15.37 bn |
AMP Ameriprise Financial | 2.63 mm | $14.81 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Mar 24 | Scott Wagner | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 6.91 | 908,739 | 6.28 mm | 908,739 |
16 Mar 24 | Scott Wagner | RSU Class A Common Stock | Grant | Acquire A | No | No | 0 | 564,732 | 0.00 | 564,732 |
12 Mar 24 | Romin Nabiey | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 7.22 | 51,462 | 371.56 k | 51,462 |
12 Mar 24 | Romin Nabiey | RSU Class A Common Stock | Grant | Acquire A | No | No | 0 | 35,716 | 0.00 | 35,716 |
12 Mar 24 | Karsten Voermann | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 7.22 | 515,793 | 3.72 mm | 515,793 |
12 Mar 24 | Karsten Voermann | RSU Class A Common Stock | Grant | Acquire A | No | No | 0 | 357,168 | 0.00 | 357,168 |
8 Mar 24 | Romin Nabiey | Class A Common Stock | Payment of exercise | Dispose F | No | No | 7.54 | 3,745 | 28.24 k | 115,997 |
8 Mar 24 | Romin Nabiey | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 10,201 | 0.00 | 119,742 |
8 Mar 24 | Romin Nabiey | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 10,201 | 0.00 | 102,008 |
8 Mar 24 | Karsten Voermann | Class A Common Stock | Payment of exercise | Dispose F | No | No | 7.54 | 17,240 | 129.99 k | 211,952 |
News
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
25 Mar 24
Telemedicine GoodRx Has Potential To Excel, Close Valuation Gap By 2025, Analyst Says
25 Mar 24
The Latest Analyst Ratings For GoodRx Holdings
25 Mar 24
Esperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market Session
25 Mar 24
Wells Fargo Upgrades GoodRx Holdings to Overweight, Announces $10 Price Target
25 Mar 24
Press releases
GoodRx Interim CEO Extends Commitment to Company
14 Mar 24
GoodRx Reports Fourth Quarter and Full Year 2023 Results
29 Feb 24
GoodRx Announces Proposed Refinancing of First Lien Credit Facilities
22 Jan 24
The GoodRx Effect: Delivering a Transformative Impact on the U.S. Healthcare System through Prescription Savings
11 Jan 24
GoodRx Announces Preliminary Fourth Quarter and Full Year 2023 Results and Early Expectations for First Quarter and Full Year 2024
10 Jan 24